Abstract
This clinical report describes durable control of disease in a postmenopausal patient receiving hemodialysis and letrozole plus lapatinib since the diagnosis of HER2-positive, estrogen receptor-positive liver metastasis from breast cancer after anastrozole plus trastuzumab failure.
Keywords
Get full access to this article
View all access options for this article.
References
1.
Konecny G.E.
,
Pegram M.D.
,
Venkatesan N.
,
Finn R.
,
Yang G.
,
Rahmeh M.
,
Untch M.
,
Rusnak D.W.
,
Spehar G.
,
Mullin R.J.
,
Keith B.R.
,
Gilmer T.M.
,
Berger M.
,
Podratz K.C.
,
Slamon D.J.
: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res , 66 : 1630 –1639 , 2006 .
2.
Crivellari D.
,
Spazzapan S.
,
Lombardi D.
,
Militello L.
,
Torrisi E.
,
Russo A.E.
,
Sorio R.
,
Talamini R.
,
Miolo G.
,
Carli P.
,
Veronesi A.
: Lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a single institution experience. Tumori , 98 : 33 –38 , 2012 .
3.
Schwartzberg L.S.
,
Franco S.X.
,
Florance A.
,
O'Rourke L.
,
Maltzman J.
,
Johnston S.
: Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist , 15 : 122 –129 , 2000 .